Method for stabilizing halogenated hydrantoins, comprising mixing the hydantoin with dry calcium hydroxide.

Patent
   5780641
Priority
Dec 25 1995
Filed
Dec 19 1996
Issued
Jul 14 1998
Expiry
Dec 19 2016
Assg.orig
Entity
Large
35
22
all paid
14. Stabilized halogenated hydantoin composition, comprising an halogenated hydantoin and ca(OH)2.
1. Method for stabilizing halogenated hydantoins, comprising mixing the hydantoin with dry calcium hydroxide.
9. Method for storing hydantoin, which comprises preparing an intimate mixture of the hydantoin and ca(OH)2, and forming the resulting composition in shape retentive form.
2. Method according to claim 1, wherein the calcium hydroxide contains no more than 1% by weight of water.
3. Method according to claim 1, wherein the hydantoin is selected from the group consisting of chlorinated alkyl-hydantoin, brominated alkyl-hydantoin, and mixtures thereof, wherein the chlorinated alkyl hydantoin and brominated alkyl-hydantoin have the formula ##STR2## wherein R1 and R2 are lower alkyl groups, X1 and X2 are Br or Cl, independently.
4. Method according to claim 1, wherein the amount of calcium hydroxide is from 0.1% to 12% of the total composition.
5. Method according to claim 4, wherein the amount of calcium hydroxide is from 0.25% to 6% of the total composition.
6. Method according to claim 1, wherein the calcium hydroxide is intimately mixed with the hydantoin.
7. Method according to claim 1, wherein the hydantoin is chosen from among the dibromo-, dichloro- and chlorobromo-derivatives of 5,5-dimethyl-hydantoin, 5-ethyl-5-methyl-hydantoin and 5,5-diethyl-hydantoin.
8. Method for storing halogenated hydantoin, which comprises the steps of preparing an intimate mixture of the hydantoin and ca(OH)2 according to claim 1 and storing the same in closed containers.
10. Method according to claim 9, wherein the shape retentive form is chosen from among briquettes, tablets and granules.
11. Method according to claim 9, wherein intimate mixture of hydantoin and ca(OH)2 further comprises the processing facilitating ingredients selected from lubricants, binders and dissolution aids.
12. Method according to claim 9, which comprises compacting the hydantoin-ca(OH)2 and processing ingredients mixture.
13. Method according to claim 9, which comprises forming the hydantoin-ca(OH)2 and processing ingredients into tablets or briquettes.
15. Composition according to claim 14, which comprises water in an amount of not more than 1% of the weight of the ca(OH)2.
16. Composition according to claim 14, which comprises additional components.
17. Composition according to claim 16, wherein the additional component is boric acid.
18. Composition according to claim 14, in shape retentive form.
19. Composition according to claim 18, wherein the shape retentive form is chosen from among briquettes, tablets and granules.
20. Composition according to claim 14, wherein the hydantoin is chosen from among 1,3-dibromo-5,5-dimethylhydantoin, 1-bromo-3-chloro-5,5-dimethyldantoin and 1,3-dichloro-5,5-dimethylhydantoin.
21. Composition according to claim 14, wherein the amount of calcium hydroxide is from 0.1% to 12% of the total composition.
22. Composition according to claim 14, wherein the amount of calcium hydroxide is from 0.25% to 6% of the total composition.

This invention is directed to a method for stabilizing halogenated alkyl-hydantoins (hereinafter designated sometimes as "DHDAH"), to a method for storing the same, particularly after packaging them in either powder, granular or tablet form, to compositions of matter comprising stabilized DHDAH, and to stable, shape retentive products comprising DHDAH as a halogen donor.

The halogenated alkyl-hydantoins to which this is invention is particularly directed have the general formula ##STR1## wherein R1 and R2 are lower alkyl groups, i.e., C1 -C4 alkyl groups, and X1 and X2 are Br or Cl, independently.

A number of halogenated alkyl-hydantoins are well-known for their bleaching and disinfecting properties. Their effectiveness in these applications is due to their ability to generate (release) positive halogen in aqueous solution. Typical alkyl-hydrantoins are, for example, 5,4-dimethyl-hydantoin, 5-ethyl-5-methyl-hydantoin and 5,5-diethylhydantoin. Typical halogenated alkyl-hydantoins are the dichloro-, dibromo- and chlorobromo- derivatives of said alkyl-hydantoins.

In many applications, it is desirable to press the halogenated hydantoins in a shape retentive form, i.e., as a granule, tablet or briquette, due to the inherently irritating and dusty nature of the compounds.

Halogenated alkyl-hydantoins (e.g., 1,3-dibromo-5,5-dimethylhydantoin, 1-bromo-3-chloro-5,5-dimethyldantoin and 1,3-dichloro-5,5-dimethylhydantoin) are halogen donors typically utilized for various purposes. Thus, 1-bromo-3-chloro-5,5-dimethylhydantoin is used form swimming pool sanitizers, while 1,3-dichloro-5,5-dimethylhydantoin has been used successfully for bleaching (see, Kirk-Othmer, Encyclopedia of Chemical technology, Volume 12, pp. 704-705, Wiley Interscience, 1980; and U.S. Pat. No. 2,779,764).

One of the disadvantages of ordinary commercial halogenated hydantoins products is that the halogenated hydantoins tends to release free halogen with time, heat or exposure to sunlight while in storage. The release of halogen is desired in the use of the products for the water treatment in pools, spas, cooling towers, toilets and the like and in fact the action of the products is based on such release. However, release of halogen during storage results in the exposure of personnel to halogen when the containers, in which the products have been stored, are opened.

It is an object of this invention to provide a method of preparing substantially stable halohydantoin compositions. By "substantially stable" is meant herein a composition which does not decompose with evolution of halogen gas--viz. is no "degased", and therefore does not release halogen gas in a closed packing container--above acceptable limits. More precisely, a halohydantoin composition is considered substantially stable, as this expression is used in this specification and claims, when it passes the "Stability Test", hereinafter set forth.

It is another object of this invention to provide a method of storing halohydantoins, particularly after packaging them in either powder, granular or tablet form.

It is a further object of this invention to provide compositions of matter comprising stabilized halohydantoins, that are suitable for storing without undergoing degassing.

It is a still further object of this invention to provide stable, shape retentive products comprising halohydantoins as halogen donors.

Other objects and advantages of the invention will appear as the description proceeds.

According to the invention, halogenated hydantoins are stabilized by mixing therewith dry calcium hydroxide. By "dry calcium hydroxide" is meant calcium hydroxide that contains no more than 1% by weight of water. All the percentages in this specification and claims are by weight, unless otherwise specified.

The amount of Ca(OH)2 used is preferably from 0.25 to 4-6% of the aggregate amount of DHDAH and Ca(OH)2. Increasing the amount above 4% does not produce any substantial improvement and may cause pH problems in the operation. However, the invention will still be operative at such higher amounts and therefore there are no fixed upper limits to the amount of Ca(OH)2 used, which can be as high as 12% and even higher. Further, while it is desirable to use at least 0.25% of Ca(OH)2, lower amounts--e.g. as low as 0.1% and even lower--may be used while still achieving some stabilizing effect.

The halohydantoin and the Ca(OH)2 should be intimately mixed to produce a homogenous product. Mechanical means for carrying out said mixing are available in the art and well known to skilled persons.

The halogenated hydantoins, to which this invention relates, are particularly, but not exclusively, alkylated, more particularly methylated hydantoins, and the halogens are bromine and/or chlorine.

The method for storing the halogenated hydantoins comprises preparing an intimate mixture of the hydantoin and Ca(OH)2, and storing it in closed containers. In a form of the invention, the said method further comprises adding other ingredients to facilitate processing or for other purposes, and forming the resulting composition in shape retentive form, before storing it. The shape retentive form can be, e.g., that of briquettes, tablets or the like, or of granules. Alternatively, the composition can be stored in powder form, without further processing. The processing facilitating ingredients may be, e.g., as lubricants, binders, dissolution aids, and the like. After the hydantoin-Ca(OH)2 mixture has been mixed with the processing ingredients, it is compacted and/or into tablets, briquettes, or other shape retentive forms. Whatever its final form, when the composition is stored in closed packing containers, marketed and used, the problem of halogen gas release and build-up in the containers does not arise, or arises to a significantly lower degree than in the case of the halogenated hydantoins and halogenated hydantoin formulations of the prior art.

The shape retentive forms of the composition are an aspect of the invention.

The use of Ca(OH)2 as a stabilizers for halohydantoins is another aspect of the invention.

The following examples illustrate but do not limit the invention and illustrate its advantages.

PAC Preparation of the Stabilized Composition

The halogenated hydantoin to be stabilized is charged in dry, powder form, preferably with an average grain size comprised between 60 and 160μ, into a mixer. The mixer is a two-ton maximum load drum. It is built on its side in an elongated position. The material is top loaded. Inside the drum are 5 angled paddles, which turn counter to a continuous outer auger stripe. The outer agitator continuously pulls the material off the bottom of the drum and moves it counter to the inner material. Analysis shows that the material being mixed is homogeneous after one hour. However, the mixing is carried out for two hours. The desired percentage of Ca(OH)2, previously dried to a water content below 0.5%, is also charged into the mixer. The mixer is then actuated at a speed of 23 rpm during 120 minutes, at room temperature. The environment humidity is controlled to prevent the mixture from acquiring an undesired degree of moisture. A homogeneous, powdery mixture is thus obtained. The powdery mixture may be granulated or tabletted by conventional means, if desired.

Skilled persons will easily be able to apply modified or different mixing, granulating and tabletizing techniques and equipment known in the art. All the compositions mentioned in the following examples have been prepared as described in this Example 1.

The following Examples show the improved stability of the compositions according to the invention over those of the prior art. Said stability was evaluated by determining as follows the amount of halogen released from the halogenated hydantoins. In the examples, dihalogenated dialkyl-hydantoins (indicated by DHDAH) have been used for purposes of illustration, but this should not be construed as a limitation of the invention, and the operations described could be carried out with any halogenated hydantoin.

A known amount of DHDAH was placed inside a 1 liter Erlenmeyer flask equipped with a ground glass fit flow tube and an exhaust provided with a glass fiber filter so as not to allow said DHDAH to escape from the flask into the KI solution, hereinafter mentioned. Halogen release was effected by one of the following methods:

Method A) The DHDAH was heated to various temperatures for various times, while a slow stream of N2 was passed through the flask via the flow tube into a solution of 2% KI, which was then titrated with standard NaS2 O3.

Method B) The DHDAH was allowed to stand in room light at room temperature for various periods of time, while a slow continuous stream of N2 was passed through the flask via the flow tube into a solution of 2% KI, which was then titrated with standard NaS2 O3.

Method C) The aforementioned method A was used, but the N2 was not passed through until the end of the heat treatment, followed by 15 minutes cooling time.

A particular embodiment of Method C constitutes the stability test:

The composition to be tested, comprising the halogenated hydantoin and the C(OH)2, is placed inside a 1 liter Erlenmeyer flask equipped with a ground glass fit flow tube and an exhaust provided with a glass fiber filter. The composition is heated to 80°C for 4 hours. After 4.5 hours, a stream of N2 is passed through the flask via the flow tube into a solution of 2% KI, which is then titrated with standard NaS2 O3. The composition passes the stability test, and is considered "stable", as this term is to be construed in this application, if the amount of halogen determined by the titration is less than 50 ppm per 100 grams of composition tested.

A composition that passes the stability test will now show, ordinarily, any red color at the end of the test, and the observation of the color may constitute an abbreviated, though less precise, stability test. Further, a composition that passes the stability test will not, ordinarily, evolve any significant amount of halogen if it is kept at 25°C or below.

Formulations of fresh dry DHDAH containing various concentrations of calcium hydroxide, having less than 0.5% water, were mixed to homogeneity and then subjected to various halogen evolution conditions, viz. heating and/or exposure to sunlight, and the halogen evolution determined by one of Methods A, B and C described above.

The DHDAH used in the following examples was BCDMH (1-bromo-3-chloro-5,5-dimethylhydantoin). All samples were in powder form unless specified. All percentages are by weight. All samples had a weight of 100 grams of aggregate BCDMH and Ca(OH)2 in a 1 liter Erlenmeyer flask. The amount of bromine evolved is expressed in all the Tables as ppm of halogen, calculated as Br, for 100 grams of sample. Should a sample be larger, a proportionately larger number of ppm would of course be found.

Five samples were prepared as in Example 1 and tested according to Method A. The amount of Ca(OH)2 added is shown in the following table. All samples were monitored for total halogen evolution.

TABLE I
______________________________________
Temperature Time
Sample % Ca(OH)2
°C. hr Br2
______________________________________
1-1 0 80 5 415
1-2 0.25 80 2.5 16
1-3 0.5 80 2.5 21
1-4 1 80 5 42.6
1-5 2 80 5 21.3
______________________________________

These data show quite clearly the drastic reduction in the halogen evolution, due to the invention, with even as little as 0.25% Ca(OH)2.

In this example samples of stabilized BCDMH-Ca(OH)2 compositions were subjected to heating and their stability was tested to determine the effect of the heating time. Four samples were prepared and tested according to Method A. The amount of Ca(OH)2 used is shown in the following table.

TABLE II
______________________________________
Temperature Time
Sample % Ca(OH)2
°C. hr Br2
______________________________________
2-1 0 80 4 231
2-2 0.5 80 4 61
2-3 0 80 5 319
2-4 0.5 80 5 97
______________________________________

These data show that a 0.5% content of Ca(OH)2 is still effective in stabilizing after five hours of heating.

Four samples of stabilized BCDMHA-Ca(OH)2 compositions, with different amounts of Ca(OH)2, were prepared and tested at 95°C for 5 hours according to Method C. The results are shown in the following table.

TABLE III
______________________________________
Temperature Time
Sample % Ca(OH)2
°C. hr Br2
______________________________________
3-1 0 95 5 462
3-2 1 95 5 8.6
3-3 2.5 95 5 2.8
3-4 4 95 5 2
______________________________________

These data show that 1% Ca(OH)2 is still effective in reducing halogen evolution at 95°C

Four samples of each of 3 batches of BCDMH-Ca(OH)2 compositions were prepared and tested according to Method C. Each set of 4 samples included one comparative sample (zero Ca(OH)2) and 3 samples stabilized with Ca(OH)2. The test data and results are shown in the following table.

TABLE IV
______________________________________
Temperature Time
Sample % Ca(OH)2
°C. hr Br2
______________________________________
4-1 0 25 7 265
4-2 1 25 7 1
4-3 2.5 25 7 0
4-4 4 25 7 0
4-5 0 25 7 383
4-6 1 25 7 0
4-7 2.5 25 7 3
4-8 4 25 7 0
4-9 0 25 7 311
4-10 1 25 7 4
4-11 2.5 25 7 3
4-12 4 25 7 0.5
______________________________________

These data show that 1% Ca(OH)2 is effective in reducing the degassing effect.

In this example, the effect of sunlight on halogen degassing is studied. In addition to samples stabilized with Ca(OH)2, other samples containing Na2 CO3 or Mg(OH)2 were prepared and tested. The samples were placed in direct sunlight. The samples were observed for the presence of halogen degassing. The resulting appearance of the flasks is defined in the following table as "no halogen observed" (NO), "slight red color" (SLIGHT), "red color" (RED), "dark red color" (DARK R).

TABLE V
______________________________________
BATCH #
% Ca(OH)3
% Na2 CO3
% Mg(OH)2
Days Observed
______________________________________
5-1 0 0 0 3 DARK R
5-2 3 0 0 3 NO
5-3 0 3 0 3 RED
5-4 0 0 3 3 SLIGHT
5-5 0 0 0 3 DARK R
5-6 3 0 0 3 NO
5-7 0 3 0 3 SLIGHT
5-8 0 0 3 3 SLIGHT
5-9 0 0 0 1 RED
5-10 2 0 0 1 NO
5-11 0 2 0 1 SLIGHT
5-12 0 0 2 1 SLIGHT
5-13 0 0 0 2 DARK R
5-14 1 0 0 2 NO
5-15 0 1 0 2 RED
5-16 0 0 1 2 SLIGHT
5-17 0 0 0 7 DARK R
5-18 4 0 0 7 NO
5-19 0 4 0 7 SLIGHT
5-20 0 0 4 7 RED
5-21 0 0 0 7 DARK R
5-22 2.5 0 0 7 NO
5-23 0 2.5 0 7 DARK R
5-24 0 0 2.5 7 RED
5-25 0 0 0 30 DARK R
5-26 3 0 0 30 NO
5-27 0 3 0 30 RED
5-28 0 0 3 30 RED
______________________________________

These tests show that while Na2 CO3 and Mg(OH)2 show some stabilizing effect, Ca(OH)2 is considerably superior.

In this example, the amount of degassing is determined for three batches--D, E and F--each tested in powder, granule and tablet form. Three samples of each of three batches were prepared from BCDMH and Ca(OH)2 as described in Example 1 and tested according to Method C. The results of the tests are shown below

TABLE VI
______________________________________
Temperature
Time
Batch Form % Ca(OH)3
°C.
hr. Br2
______________________________________
D POWDER 2.5 80 20 0.4
D GRANULE 2.5 80 20 0.8
D TABLET 2.5 80 20 .06
E POWDER 3 80 20 1
E GRANULE 3 80 20 1.7
E TABLET 3 80 20 1.9
F POWDER 4 80 20 .06
F GRANULE 4 80 20 .14
F TABLET 4 80 20 .66
______________________________________

These data show that Ca(OH)2 is an effective stabilizer for DHDAH, whether in powder, granular and tablet form.

This example shows the effect of time on the stabilizing effect of Ca(OH)2, when used in conjunction with a binding agent such as boric acid. Four samples were prepared and tested according to Method A. The results of the tests are shown in the following table.

TABLE VII
______________________________________
Temperature
Time
Sample % Boric % Ca(OH)2
°C.
hour Br2
______________________________________
B-1 0 0 80 4 70
B-2 4 1 80 4 2
B-3 3 2 80 5 4
B-4 2 3 80 5 4
B-5 5 0 80 4 93
______________________________________

These data show that Ca(OH)2 is effective in combination with boric acid.

While certain embodiments of the invention have been described by way of illustration, it will be apparent that the invention can be carried into practice by persons skilled in the art with many modifications, variations and adaptations, without departing from its spirit or exceeding the scope of the claims.

Yerushalmi, Moshe, Vainberger, Zvi, Herbet, Shimon, Rasco, James

Patent Priority Assignee Title
10092853, Dec 19 2012 NIPPOH CHEMICALS CO., LTD. Apparatus for producing halohydantoin compound
11802246, Mar 11 2021 BAKER HUGHES OILFIELD OPERATIONS LLC Synergistic effects among mercaptan scavengers
6124251, Oct 27 1995 The Clorox Company Toilet bowl cleaning tablet
6303038, Jun 01 1999 Albemarle Corporation Solid mixtures of dialkylhydantoins and bromide ion sources for water sanitization
6448410, Jan 18 2000 Albemarle Corporation Production of compacted biocidal agent from particulate biocidal agent without using a binder
6495698, Jan 18 2000 Albemarle Corporation Binder-free compacted forms of 1,3-dihalo-5,5-dimethylhydantoins
6508954, Jan 18 2000 Albemarle Corporation 1,3-dibromo-5,5-dimethylhydantoin of enhanced properties
6565868, Jan 18 2000 Albemarle Corporation Methods for microbiological control in aqueous systems
6638959, Jan 18 2000 Albemarle Corporation Microbiological control in aqueous systems
6680070, Jan 18 2000 Albemarle Corporation Particulate blends and compacted products formed therefrom, and the preparation thereof
6749758, Dec 05 2001 Albemarle Corporation Methods and systems for uniform-control of bromine concentrations in water
6809205, Jan 18 2000 Albemarle Corporation Process for producing N-halogenated organic compounds
6908636, Jun 28 2001 Albermarle Corporation Microbiological control in poultry processing
6919364, Jun 28 2001 Albemarle Corporation Microbiological control in animal processing
6965035, Jul 25 2002 Albemarle Corporation Compacted forms of halogenated hydantoins
6986910, Jun 28 2001 Albemarle Corporation Microbiological control in poultry processing
7172782, Jun 28 2001 Albemarle Corporation Microbiological control in poultry processing
7182966, Jun 28 2001 Albemarle Corporation Microbiological control in poultry processing
7371397, Jan 18 2000 Albemarle Corporation Methods for microbiological control in aqueous systems
7579018, Jan 18 2000 Albemarle Corporation Microbiological control in aqueous systems
7767240, Jun 28 2001 Albemarle Corporation Microbiological control in poultry processing
7897785, Sep 02 2005 NIPPOH CHEMICALS CO , LTD 1,3-Diiodohydantoin compound and production method thereof
7901276, Jun 24 2003 Albemarle Corporation Microbiocidal control in the processing of meat-producing four-legged animals
7914365, Dec 01 2005 Albemarle Corporation Microbiocidal control in the processing of meat-producing four-legged animals
7985413, Jan 18 2000 Albemarle Corporation Microbiological control in aqueous systems
7999118, Jan 18 2000 Albemarle Corporation Process for producing N-halogenated hydantoins
8586763, Jan 18 2000 Albemarle Corporation Process for producing N-halogenated hydantoins
8710240, Sep 02 2005 NIPPOH CHEMICALS CO., LTD. 1,3-diiodohydantoin compound and production method thereof
8722902, Sep 02 2005 Nippon Chemicals Co., Ltd. 1,3-diiodohydantoin compound and production method thereof
8772506, Sep 02 2005 NIPPOH CHEMICALS CO., LTD. 1,3-diiodohydantoin compound and production method thereof
9029562, Jan 18 2000 Albemarle Corporation Process for producing N-halogenated hydantoins
9656967, Mar 19 2013 NIPPOH CHEMICALS CO , LTD Method for producing halohydantoin compound
9834517, Dec 19 2012 NIPPOH CHEMICALS CO , LTD Method for producing halohydantoin compound and halohydantoin compound
9855514, Dec 19 2012 NIPPOH CHEMICALS CO , LTD Method and apparatus for producing halohydantoin compound, recycling method, and halohydantoin compound
9962624, Dec 19 2012 NIPPOH CHEMICALS CO., LTD. Recycling method
Patent Priority Assignee Title
2430233,
2779764,
2795556,
2868787,
2920997,
2934451,
2971959,
2971960,
2986555,
3121715,
3147219,
3345371,
3352860,
3412021,
4532330, Sep 30 1982 Great Lakes Chemical Corporation Process for producing densified halogenated dimethylhydantoins
4560766, Feb 09 1983 LONZA INC Shaped halogenated hydantoins
4654424, Feb 02 1983 LONZA INC Method for preparing halogenated hydantoins
4677130, Oct 07 1985 Great Lakes Chemical Corporation Process of densification of N-halohydantoin compositions and products thereof
4681948, Mar 31 1986 PPG INDUSTRIES, INC ,; Auburn Research Foundation N,N'dihalo-2-imidazolidinones
4698165, Oct 18 1985 LONZA INC Shock treatment of aqueous systems
4745189, Jun 23 1986 Albermarle Corporation Method of preparing N-halogenated organic heterocyclic compounds
EP394529,
/////
Executed onAssignorAssigneeConveyanceFrameReelDoc
Dec 19 1996Bromine Compounds Ltd.(assignment on the face of the patent)
Jan 14 1997VAINBERGER, ZVIBROMINE COMPOUNDS LTDASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0084390628 pdf
Jan 22 1997HERBET, SHIMONBROMINE COMPOUNDS LTDASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0084390628 pdf
Jan 22 1997RASCO, JAMESBROMINE COMPOUNDS LTDASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0084390628 pdf
Jan 30 1997YERUSHALMI, MOSHEBROMINE COMPOUNDS LTDASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS 0084390628 pdf
Date Maintenance Fee Events
Jan 14 2002M183: Payment of Maintenance Fee, 4th Year, Large Entity.
Jan 22 2002ASPN: Payor Number Assigned.
Jan 22 2002RMPN: Payer Number De-assigned.
Dec 27 2005M1552: Payment of Maintenance Fee, 8th Year, Large Entity.
Dec 22 2009M1553: Payment of Maintenance Fee, 12th Year, Large Entity.


Date Maintenance Schedule
Jul 14 20014 years fee payment window open
Jan 14 20026 months grace period start (w surcharge)
Jul 14 2002patent expiry (for year 4)
Jul 14 20042 years to revive unintentionally abandoned end. (for year 4)
Jul 14 20058 years fee payment window open
Jan 14 20066 months grace period start (w surcharge)
Jul 14 2006patent expiry (for year 8)
Jul 14 20082 years to revive unintentionally abandoned end. (for year 8)
Jul 14 200912 years fee payment window open
Jan 14 20106 months grace period start (w surcharge)
Jul 14 2010patent expiry (for year 12)
Jul 14 20122 years to revive unintentionally abandoned end. (for year 12)